Clinical Trial Update: HL-085 in NRAS-mutated Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for HL-085 in NRAS-mutated advanced melanoma has completed enrollment and is in Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• HL-085

Snippet

Sponsor: Shanghai Kechow Pharma, Inc. | Conditions: Melanoma | Phase 2 | Status: COMPLETED